Alaunos Therapeutics Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Alaunos Therapeutics (TCRT) filed its Q1 2024 10-Q, outlining financial performance and key operational agreements.</b>

AI Summary

Alaunos Therapeutics, Inc. (TCRT) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Alaunos Therapeutics, Inc. (TCRT) filed a 10-Q for the quarter ended March 31, 2024. The filing details financial activities and business operations for the specified period. Key dates and agreements mentioned include the MDAnderson License and Research and Development Agreement (2015-08-17) and the Collaboration Agreement with Solasia Pharma KK (2024-01-01 to 2024-03-31). The company's former names include ZIOPHARM ONCOLOGY INC and EASYWEB INC. Financial instruments and agreements such as warrants, royalty payments, and loans from Silicon Valley Bank are referenced.

Why It Matters

For investors and stakeholders tracking Alaunos Therapeutics, Inc., this filing contains several important signals. This 10-Q provides investors with the latest financial snapshot of Alaunos Therapeutics, crucial for understanding its current financial health and operational status. The filing includes details on various agreements and financial instruments, offering insights into the company's strategic partnerships and funding mechanisms.

Risk Assessment

Risk Level: medium — Alaunos Therapeutics, Inc. shows moderate risk based on this filing. The company's financial disclosures in this 10-Q are standard for a public company, but the lack of specific financial performance metrics (revenue, net income, etc.) in the provided text prevents a more detailed risk assessment.

Analyst Insight

Review the full 10-Q filing for detailed financial statements, including revenue, expenses, and cash flow, to assess the company's financial performance and future prospects.

Key Numbers

• 2024-03-31 — Reporting Period End Date (10-Q filing)
• 2024-05-15 — Filing Date (10-Q filing)
• 2015-08-17 — MDAnderson License and R&D Agreement Date (Key agreement date)
• 2024-01-01 to 2024-03-31 — Collaboration Agreement Period (Solasia Pharma KK agreement)

Key Players & Entities

• Alaunos Therapeutics, Inc. (company) — Filer name
• TCRT (company) — Ticker symbol
• ZIOPHARM ONCOLOGY INC (company) — Former company name
• EASYWEB INC (company) — Former company name
• The University of Texas MD Anderson Cancer Center (company) — Partner in agreements
• Solasia Pharma KK (company) — Partner in collaboration agreement
• Silicon Valley Bank (company) — Lender
• 2024-03-31 (date) — End of reporting period

FAQ

Risk Factors

• Financial Condition [medium — financial]: The filing provides information on the company's financial condition as of March 31, 2024, but specific details on revenue, profitability, and cash reserves are not detailed in the provided text.
• SEC Reporting Compliance [low — regulatory]: The company is filing a Form 10-Q, which is a standard quarterly report required by the SEC, indicating compliance with ongoing disclosure obligations.

Key Dates

• 2024-03-31: Quarterly Period End — Financial data reported as of this date.
• 2024-05-15: Filing Date — Date the 10-Q was officially submitted to the SEC.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC). (Provides investors with a comprehensive overview of a company's financial performance during the quarter.)

Key Financial Figures

• $0.001 — hares of the registrant's common stock, $0.001 par value, was 16,012,522 shares. SPE

Filing Documents

• tcrt-20240331.htm (10-Q) — 1201KB
• tcrt-ex10_1.htm (EX-10.1) — 1KB
• tcrt-ex10_1.pdf (EX-10.1) — 198KB
• tcrt-ex31_1.htm (EX-31.1) — 13KB
• tcrt-ex32_1.htm (EX-32.1) — 7KB
• 0000950170-24-060075.txt (&nbsp;) — 5089KB
• tcrt-20240331.xsd (EX-101.SCH) — 941KB
• tcrt-20240331_htm.xml (XML) — 483KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 22 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 23 Item 1A.

Risk Factors

Risk Factors 23 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 50 Item 3. Defaults Upon Senior Securities 50 Item 4. Mine Safety Disclosures 50 Item 5. Other Information 50 Item 6. Exhibits 51 1

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Condensed Financial Statements

Item 1. Condensed Financial Statements Alaunos Therapeutics, Inc. CONDENSED BALANCE SHEETS (unaudited) (in thousands, except share and per share data) March 31, December 31, 2024 2023 ASSETS: Current assets: Cash and cash equivalents $ 4,145 $ 6,062 Receivables 1 1 Prepaid expenses and other current assets 1,891 2,198 Total current assets 6,037 8,261 Property and equipment, net — 2 Total assets $ 6,037 $ 8,263 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 597 $ 616 Accrued expenses 643 1,340 Total current liabilities 1,240 1,956 Total liabilities $ 1,240 $ 1,956 Commitments and contingencies (Note 8) Stockholders' equity Common stock $ 0.001 par value; 34,666,667 shares authorized, 16,012,522 shares issued and outstanding at March 31, 2024 and at December 31, 2023 16 16 Additional paid-in capital 922,230 922,058 Accumulated deficit ( 917,449 ) ( 915,767 ) Total stockholders' equity 4,797 6,307 Total liabilities and stockholders' equity $ 6,037 $ 8,263 The accompanying notes are an integral part of these condensed financial statements. 2 Alaunos Therapeutics, Inc. CONDENSED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) For the Three Months Ended March 31, 2024 2023 Collaboration revenue $ 1 $ — Operating expenses: Research and development 126 6,504 General and administrative 1,617 3,168 Total operating expenses 1,743 9,672 Loss from operations ( 1,742 ) ( 9,672 ) Other income (expense): Interest expense — ( 853 ) Other income, net 60 477 Other income (expense), net 60 ( 376 ) Net loss $ ( 1,682 ) $ ( 10,048 ) Basic and diluted net loss per share $ ( 0.11 ) $ ( 0.63 ) Weighted average common shares outstanding, basic and diluted 16,012,522 15,978

View Full Filing

View this 10-Q filing on SEC EDGAR